WITHDRWAN: Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: a double-blinded, randomized, placebo controlled study.

Abstract

BACKGROUND:

Purified palmitoleic acid (16-1; omega-7) has shown lipid-lowering and anti-inflammatory benefits in open label, epidemiologic, and animal studies.

OBJECTIVE:

Our objective was to perform the first randomized controlled trial of purified palmitoleic acid supplementation in humans.

METHODS:

Adults with dyslipidemia and evidence of mild systemic inflammation (high-sensitivity C-reactive protein [hs-CRP] between 2 and 5 mg/L) were randomly allocated to receive either 220.5 mg of cis-palmitoleic acid (n = 30) or an identical capsule with placebo (1000 mg of medium chain triglycerides, n = 30) once per day for 30 days. Participants were asked to maintain their current diet. Serum lipids and hs-CRP were drawn at baseline and study completion.

RESULTS:

At 30 days, there were significant mean (95% confidence interval [CI]) reductions in CRP (-1.9 [-2.3 to -1.4] mg/L), triglyceride (-30.2 [-40.2 to -25.3] mg/dL), and low-density lipoprotein (LDL) (-8.9 [-12.0 to -5.8] mg/dL), and a significant increase in high-density lipoprotein (HDL) (2.4 [1.5, 3.3] mg/dL) in the intervention group compared with control. These changes equated to 44%, 15%, and 8% reductions in CRP, triglyceride, and LDL respectively, and a 5% increase in HDL compared with control.

CONCLUSIONS:

Purified palmitoleic acid may be useful in the treatment of hypertriglyceridemia with the beneficial added effects of decreasing LDL and hs-CRP and raising HDL. Further study is needed to elucidate mechanisms and establish appropriate human doses.

• Authors: Adam M Bernstein, Michael F Roizen, Luis Martinez
• Journal: Journal of clinical lipidology (J Clin Lipidol) 2014 Nov-Dec Vol. 8 Issue 6 Pg. 612-617 ISSN: 1933-2874 [Print] United States
• PMID: 25499944 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Retracted Publication)
• Copyright: Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Cholesterol, LDL
• Fatty Acids, Monounsaturated
• Hypolipidemic Agents
• Placebos
• Triglycerides
• palmitoleic acid
• C-Reactive Protein

Topics

• Adult
• Anti-Inflammatory Agents, Non-Steroidal (adverse effects, therapeutic use)
• C-Reactive Protein (metabolism)
• Cholesterol, LDL (blood)
• Dietary Supplements
• Double-Blind Method
• Dyslipidemias (diet therapy)
• Fatty Acids, Monounsaturated (adverse effects, therapeutic use)
• Female
• Humans
• Hypolipidemic Agents (adverse effects, therapeutic use)
• Inflammation (diet therapy)
• Lipid Metabolism (drug effects)
• Male
• Middle Aged
• Placebos (administration & dosage, adverse effects)
• Puerto Rico
• Triglycerides (blood)